Breakthrough candida infection in a preterm infant with congenital cutaneous Candida albicans infection

Amos Adler*, Ita Litmanovitz, Rivka Regev, Shmuel Arnon, Sophia Bauer, Tzipora Dolfin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Amphotericin B is the primary antifungal agent used for candida sepsis in neonates. Breakthrough candidemia was not reported in neonates during either amphotericin B or liposomal amphotericin B (AmBisome) treatment. We describe a case of a premature infant with congenital cutaneous candida infection, who had two episodes of breakthrough infection, from Candida albicans and Candida parapsilosis, while he was treated with amphotericin B and AmBisome, respectively. We discuss the pathogenesis of breakthrough infections, and the relevance of antifungal resistance and sensitivities testing.

Original languageEnglish
Pages (from-to)169-172
Number of pages4
JournalAmerican Journal of Perinatology
Volume22
Issue number3
DOIs
StatePublished - Apr 2005

Keywords

  • Amphotericin B
  • Antifungal susceptibilities testing
  • Congenital cutaneous candidiasis
  • Fluconazole

Fingerprint

Dive into the research topics of 'Breakthrough candida infection in a preterm infant with congenital cutaneous Candida albicans infection'. Together they form a unique fingerprint.

Cite this